Term ends Jan 28, 2031 · High confidence
20-year base term ends Jan 28, 2031
Jan 28, 2011
Jan 28, 2031
Feb 21, 2017
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 2 of 3 maintenance fees are paid so far. Confidence: High. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jan 28, 2011, when application 13/016,473, the earliest non-provisional in its chain, was filed (this one was filed Feb 2, 2016) | Jan 28, 2031 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 8,609,707, US 9,000,021, US 9,034,908, US 9,144,568, US 9,265,831, US 9,572,796) | resolves to Jan 28, 2031, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Jan 28, 2031 | High confidence |
This family
| US 8,609,707 | In force Jan 2031 | Jan 2031 |
| Application 61/598,729 | Provisional application no patent term | no patent term |
| Application 13/767,672 | Abandoned not computed | not computed |
| US 9,265,831 | In force Jan 2031 | Jan 2031 |
| US 9,572,796 | In force Jan 2031 | Jan 2031 |
| US 9,572,797 | this patent Jan 2031 | Jan 2031 |
| US 10,010,533 | In force Jan 2031 | Jan 2031 |
| Application 16/015,580 | Abandoned not computed | not computed |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jan 26, 2017 Reel 41095, frame 554 | Eagle Pharmaceuticals, Inc. | JPMorgan Chase Bank, N.A., as Administrative Agent | Security Interest |
| Apr 1, 2025 Reel 70703, frame 524 | JPMorgan Chase Bank, N.A., as Administrative Agent | Eagle Pharmaceuticals, Inc. | Release of Security Interest |
| May 14, 2025 Reel 71275, frame 866 | Eagle Subi LLC, a Delaware Corporation | LSI Financing LLC | Security Interest |
| Feb 18, 2026 Reel 74849, frame 457 | Eagle Pharmaceuticals, Inc. | Ankura Trust Company, LLC. | Grant of Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
A terminal disclaimer resolved from the filed document, referencing US 8,609,707, US 9,000,021, US 9,034,908, US 9,144,568, US 9,265,831, US 9,572,796, ends no earlier than this term, so it caps nothing.